Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab

Abstract Dyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects. Tralokinumab is FDA‐approved for the treatment of atopic dermatitis in adults and EMA‐approved for the treatment of atopic dermatitis in adults and adolescents. We, hereby, report a 40‐year‐old female with severe dyshidrotic palmoplantar eczema who was successfully treated with tralokinumab. To the best of our knowledge, this is the first report of the efficacious use of tralokinumab in dyshidrotic eczema.